Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance

被引:9
|
作者
Babrzadeh, Farbod [1 ]
Varghese, Vici [2 ]
Pacold, Mary
Liu, Tommy F.
Nyren, Pal [3 ]
Schiffer, Celia [4 ]
Fessel, W. Jeffrey [5 ]
Shafer, Robert W.
机构
[1] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Div Infect Dis, Dept Med, Stanford, CA 94305 USA
[3] KTH, AlbaNova Univ Ctr, Dept Biotechnol, Stockholm, Sweden
[4] Univ Massachusetts, Med Ctr, Dept Biochem, Worcester, MA USA
[5] Kaiser Permanente Med Care Program No Calif, Clin Trials Unit, San Francisco, CA USA
关键词
drug resistance; deep sequencing; minority variants; Sanger sequencing; ATAZANAVIR;
D O I
10.1093/jac/dks409
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs. We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing. For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9 of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0 of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture. The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
引用
收藏
页码:414 / 418
页数:5
相关论文
共 50 条
  • [21] Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease
    Lambert-Niclot, Sidonie
    Flandre, Philippe
    Malet, Isabelle
    Canestri, Ana
    Soulie, Cathia
    Tubiana, Roland
    Brunet, Christel
    Wirden, Marc
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 905 - 908
  • [22] Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance
    Spielvogel, Ean
    Lee, Sook-Kyung
    Zhou, Shuntai
    Lockbaum, Gordon J.
    Henes, Mina
    Sondgeroth, Amy
    Kosovrasti, Klajdi
    Nalivaika, Ellen A.
    Ali, Akbar
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    Swanstrom, Ronald
    ELIFE, 2023, 12
  • [23] Resistance to HIV-1 protease inhibitors
    Swanstrom, R
    Smith, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 58 - BIOT
  • [24] HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    Shafer, Robert W.
    Rhee, Soo-Yon
    Pillay, Deenan
    Miller, Veronica
    Sandstrom, Paul
    Schapiro, Jonathan M.
    Kuritzkes, Daniel R.
    Bennett, Diane
    AIDS, 2007, 21 (02) : 215 - 223
  • [25] Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance
    Mellors, JW
    Larder, BA
    Schinazi, R
    Deverson, C
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 92 - 92
  • [26] Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
    Schmit, JC
    Ruiz, L
    Clotet, B
    Raventos, A
    Tor, J
    Leonard, J
    Desmyter, J
    DeClercq, E
    Vandamme, AM
    AIDS, 1996, 10 (09) : 995 - 999
  • [27] Comparison of HIV-1 protease inhibitor susceptibility results in viraemic protease inhibitor-experienced patient samples analysed by phenotyping and by five resistance algorithms
    Paulsen, D
    Florance, A
    Liao, Q
    Boulme, R
    Shaefer, M
    Fusco, G
    Ross, L
    ANTIVIRAL THERAPY, 2002, 7 : S124 - S124
  • [28] Molecular tridimensional phenotyping predicts HIV-1 protease inhibitor resistance
    Pèpe, G
    Courcambeck, J
    Durant, J
    Dellamonica, P
    Boulme, R
    Halfon, P
    ANTIVIRAL THERAPY, 2002, 7 : S117 - S117
  • [29] Optimization of a macromolecular inhibitor of HIV-1 protease
    Dauber, DS
    McPhee, F
    Ünal, A
    Craik, CS
    ASPARTIC PROTEINASES: RETROVIRAL AND CELLULAR ENZYMES, 1998, 436 : 65 - 70
  • [30] Role of HIV-1 protease residues 71 and 89 in protease inhibitor resistance of subtype G viruses
    Gonzalez, LMF
    Van Laethem, K
    Abecasis, AB
    Soares, EAJM
    Deforche, K
    Vandamme, AM
    Camacho, R
    Soares, MA
    ANTIVIRAL THERAPY, 2005, 10 (04) : S112 - S112